|Salary:||£43,000 to £46,800 p.a.|
|Placed On:||14th February 2020|
|Closes:||15th March 2020|
Closing Date: 15/03/2020, 23:55
Length of Contract: 3 years in the first instance
The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. We provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today, The Institute of Cancer Research (ICR) leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.
Under the leadership of our Chief Executive, Professor Paul Workman FRS, the ICR is ranked as the UK’s leading academic research centre. Together with our partner The Royal Marsden, we are rated in the top five cancer centres globally.
The ICR is committed to attracting, developing and retaining the best minds in the world to join us in our mission – to make the discoveries that defeat cancer.
The Functional Genomics laboratory headed by Dr. Rachael Natrajan is a multidisciplinary laboratory with the mission to develop new treatment strategies for breast cancers resistant to standard of care therapies. The lab uses state of the art molecular profiling such as single cell sequencing and spatial genomic profiling on patient samples throughout disease progression to understand the molecular evolution of breast cancer and response to targeted therapies. Together with molecular barcoding strategies in patient derived models, mechanistic hypotheses are evaluated in vitro and in vivo and candidate biomarkers or therapeutic options are tested pre-clinically that informs the design of proof of concept clinical trials or drug discovery programmes. We have made novel advances into the understanding of genomic alterations and their impact on breast cancer in different contexts and how to target these effectively (including Natrajan et al J Pathol 2014 PMID 24395524; Maguire et al 2015 PMID 25424858; Bajrami et al Cancer Res 2014 PMID: 24240700; Natrajan et al PLOS Medicine 2015 PMID: 26881778, Maguire et al 2016 PMID: 27512948; Naidoo et al 2017 MCT PMID:29133620).
Dr Natrajan is seeking a highly experienced Senior Scientific Officer to lead on projects using single cell sequencing of clinical samples and molecular barcoding of patient derived models to generate new biological insights into the evolution of breast cancer. The candidate will perform experimental work to assess the implications of novel biology on tumour progression. You should possess a PhD in biology, biochemistry, genetics or other associated subjects or significant experience in a research environment and have an excellent track record in biomedical research. Experience in cell and molecular biology as well as working with in vitro and in vivo cancer models is highly desirable.
The candidate will benefit from close interactions with the other teams within the Centre (https://www.icr.ac.uk/our-research/research-divisions/division-of-breast-cancer-research) and the ICR.
This is a fixed term appointment for 3 years in the first instance.
The salary offered will be in the range from £43,000 to £46,800 p.a. inclusive. Starting salary will be based on previous experience. Future progression is based on annual performance review.
For informal enquiries, please contact Rachael.Natrajan@icr.ac.uk. Please note, applications must be submitted using the online application form.
Type / Role: